Abivax (ABVX) SA announced the launch of an approximately $400M underwritten public offering consisting of a public offering of its American Depositary Share, ADSs, each representing one ordinary share of the company in the U.S. All securities to be sold in the offering will be offered by the company. Leerink Partners, Piper Sandler & Co. and Guggenheim Securities are acting as joint bookrunning managers for the offering. LifeSci Capital is acting as lead manager, with BTIG and Van Lanschot Kempen acting as co-managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Trump announces tariff deal with Japan, AT&T reports Q2 beat: Morning Buzz
- Abivax price target raised to $101 from $45 at LifeSci Capital
- Abivax upgraded to Overweight from Equal Weight at Morgan Stanley
- Abivax upgraded to Overweight at Morgan Stanley after obefazimod data